- Home
- QCRH vs LKFT Comparison
QCRH vs LKFT Comparison
Compare QCRH & LKFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QCRH | LKFT |
|---|---|---|
| Founded | 1993 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 1996 | 2007 |
Fundamental Metrics
Financial Performance| Metric | QCRH | LKFT |
|---|---|---|
| Price | $103.41 | $33.92 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 6 |
| Target Price | ★ $112.83 | $30.60 |
| AVG Volume (30 Days) | 108.7K | ★ 228.5K |
| Earning Date | 10-20-2026 | 11-11-2026 |
| Dividend Yield | ★ 0.58% | N/A |
| EPS Growth | ★ 11.62 | N/A |
| EPS | ★ 6.39 | N/A |
| Revenue | ★ $165,999,610.00 | N/A |
| Revenue This Year | $1.00 | N/A |
| Revenue Next Year | $5.23 | N/A |
| P/E Ratio | $16.21 | ★ N/A |
| Revenue Growth | ★ 20.72 | N/A |
| 52 Week Low | $74.78 | $25.68 |
| 52 Week High | $108.11 | $34.49 |
Technical Indicators
Market Signals| Indicator | QCRH | LKFT |
|---|---|---|
| Relative Strength Index (RSI) | 55.63 | 70.80 |
| Support Level | $102.52 | $28.50 |
| Resistance Level | $103.48 | N/A |
| Average True Range (ATR) | 2.45 | 0.82 |
| MACD | 0.12 | 0.07 |
| Stochastic Oscillator | 51.48 | 61.97 |
Price Performance
Historical ComparisonAbout QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.
About LKFT Lakefront Biotherapeutics American Depositary Shares
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.